Search - Université de Rennes Access content directly

Filter your results

12 Results
authFullName_s : Murielle Roussel

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Arthur Bobin , Maéva Kyheng , Stephanie Guidez , Cecile Gruchet-Merouze , Valentine Richez et al.
Leukemia, 2022, 36 (3), pp.881-884. ⟨10.1038/s41375-021-01415-x⟩
Journal articles hal-03476700v1

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Murielle Roussel , Michelle Pirotte , Ornella Rizzo , Kentin Queru , Thomas Chalopin et al.
64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.10086-10087, ⟨10.1182/blood-2022-166224⟩
Conference papers hal-04071489v1

Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma

Guillemette Fouquet , Lionel Karlin , Margaret Macro , Denis Caillot , Murielle Roussel et al.
Blood, 2015, 126 (23), pp.1831
Journal articles hal-01300804v1

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

Guillemette Fouquet , Lionel Karlin , Margaret Macro , Denis Caillot , Murielle Roussel et al.
Annals of Hematology, 2018, 97 (5), pp.831-837. ⟨10.1007/s00277-018-3236-6⟩
Journal articles hal-01728968v1

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Xavier Leleu , Lionel Karlin , Brigitte Kolb , Mourad Tiab , Carla Araujo et al.
Blood, 2015, 126 (23), pp.3028
Journal articles hal-01290431v1

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Charlotte Fontan , Mourad Tiab , Pascal Godmer , Odile Luycx , Olivier Allangba et al.
Blood, 2016, 128 (25), pp.2941-2948. ⟨10.1182/blood-2016-07-726778⟩
Journal articles hal-01439375v1

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Arnaud Jaccard , Raymond L. Comenzo , Parameswaran Hari , Philip N. Hawkins , Murielle Roussel et al.
Haematologica, 2014, 99 (9), pp.1479-85. ⟨10.3324/haematol.2014.104109⟩
Journal articles hal-01064573v1

Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Stephanie Guidez , Guillemette Fouquet , Helene Demarquette , Morgane Nudel , Eileen Boyle et al.
Blood, 2015, 126 (23), pp.5379
Journal articles hal-01290429v1

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Xavier Leleu , Lionel Karlin , Margaret Macro , Cyrille Hulin , Laurent Garderet et al.
Blood, 2015, 125 (9), pp.1411-7. ⟨10.1182/blood-2014-11-612069⟩
Journal articles hal-01141134v1
Image document

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz , Lorenz Truemper , Krimo Bouabdallah , Marita Ziepert , Mathieu Leclerc et al.
Blood, 2021, 2020008825, ⟨10.1182/blood.2020008825⟩
Journal articles hal-03163608v1

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study

Charles Dumontet , Delphine Demangel , Perrine Galia , Lionel Karlin , Laurent Roche et al.
American Journal of Hematology, 2023, 98 (2), pp.264-271. ⟨10.1002/ajh.26785⟩
Journal articles hal-03980698v1

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Xavier Leleu , Michel Attal , Bertrand Arnulf , Philippe Moreau , Catherine Traulle et al.
Blood, 2013, 121 (11), pp.1968--1975. ⟨10.1182/blood-2012-09-452375⟩
Journal articles hal-01064417v1